Purpose PET/CT using O-(2-[18 F] fluoroethyl)-l-tyrosine (18 F-FET) has proven valuable in
differentiating tumor recurrence and progression from therapy-induced changes. This study …

Purpose The follow-up of glioblastoma patients after radiochemotherapy with conventional
MRI can be difficult since reactive alterations to the blood–brain barrier with contrast …

Abstract Purpose: Pseudoprogression (PsP) is characterized by therapy-associated but not
tumor growth–associated increases of contrast-enhancing glioblastoma lesions on MRI …

Accurate differentiation between tumor progression (TP) and pseudoprogression remains a
critical unmet need in neurooncology. 18F-fluciclovine is a widely available synthetic amino …

Purpose Response evaluation in patients with glioblastoma after chemoradiotherapy is
challenging due to progressive, contrast-enhancing lesions on MRI that do not reflect true …

Objectives To investigate the value of combined 18F-fluorethyltyrosine-(FET)-PET/MRI for
differentiation between recurrence and treatment-related changes in glioma patients …

Background Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine
(18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged …

In glioma patients, differentiation between tumor progression (TP) and treatment-related
changes (TRCs) remains challenging. Difficulties in classifying imaging alterations may …

Methods Fourteen patients with HGG and suspected of PSP underwent FET-PET imaging. A
set of 19 conventional and textural FET-PET features were evaluated and subjected to …

The ability to accurately differentiate treatment-related changes (ie, pseudoprogression and
radiation necrosis) from recurrent glioma remains a critical diagnostic problem in neuro …